Evidence Snapshot

Platelet-derived growth factor receptor alpha

CHEMBL2007 SINGLE PROTEIN Homo sapiens

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:38:23Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 6:38 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2007

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Platelet-derived growth factor receptor alpha as ChEMBL target CHEMBL2007, mapped to UniProt P16234. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Platelet-derived growth factor receptor alpha

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL2007

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

P16234

Platelet-derived growth factor receptor alpha

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Platelet-derived growth factor receptor alpha matters

As of 2026-09-13

Platelet-derived growth factor receptor alpha is reviewed as Platelet-derived growth factor receptor alpha (UniProt P16234); Platelet-derived growth factor receptor alpha shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 5 linked drugs keep this evidence frame grounded.; the current evidence base includes 43 approved drugs, 2664 compounds, and 1012 assays, with lead potency reaching pChEMBL 10.1.

Protein context

Platelet-derived growth factor receptor alpha

Platelet-derived growth factor receptor alpha Sequence length is 1089 aa.

Review this target as Platelet-derived growth factor receptor alpha, mapped to UniProt P16234. Sequence length is 1089 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt P16234 Protein

Disease context

neoplasm

Platelet-derived growth factor receptor alpha shows approved-linked disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 5 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AMUVATINIB, AVAPRITINIB, OLARATUMAB.

Start review with neoplasm because it currently carries approved-linked support. Linked drugs include AMUVATINIB, AVAPRITINIB, OLARATUMAB, RIPRETINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record

Approved-linked 5 linked drugs

Activity base

Portfolio and assay base

ChEMBL currently tracks 43 approved drugs, 2664 compounds, and 1012 assays for this target. The dominant activity type is IC50. CHEMBL196363 is the current potency anchor at pChEMBL 10.1.

Use CHEMBL196363 as the tractability anchor when discussing potency (pChEMBL 10.1).

Activity source · ChEMBL 36 via Core Engine

43 approved pChEMBL 10.1

Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?

Review-ready Target Rationale

One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Platelet-derived growth factor receptor alpha matters before drilling into raw source blocks.

Jump to Review Rationale

Need stable protein naming or accession mapping?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P16234, not just the summarized rationale.

Open Protein Context

Need disease fit or evidence level for program framing?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2664

Total Compounds

1012

Total Assays

Approved Drugs

IC50: 922.0, KI: 512.0, EC50: 6.0, KD: 163.0

Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Compound	pChEMBL	Type	Phase
No preferred name CHEMBL196363	10.1	Ki	—
No preferred name CHEMBL3904768	10.1	IC50	—
No preferred name CHEMBL3979322	9.7	IC50	—
No preferred name CHEMBL3940697	9.7	IC50	—
No preferred name CHEMBL3915941	9.7	IC50	—

Approved Drugs

Structure	Compound	First Approval
	QUIZARTINIB CHEMBL576982	2023
	AVAPRITINIB CHEMBL4204794	2020
	PEXIDARTINIB CHEMBL3813873	2019
	MIDOSTAURIN CHEMBL608533	2017
	TIVOZANIB CHEMBL1289494	2017
	LENVATINIB CHEMBL1289601	2015
	NINTEDANIB CHEMBL502835	2014
	NINTEDANIB ESYLATE CHEMBL3039504	2014
	REGORAFENIB CHEMBL1946170	2012
	AXITINIB CHEMBL1289926	2012
	PONATINIB CHEMBL1171837	2012
	VANDETANIB CHEMBL24828	2011
	PAZOPANIB CHEMBL477772	2009
	NILOTINIB CHEMBL255863	2007
	SUNITINIB CHEMBL535	2006
	DASATINIB CHEMBL5416410	2006
	SORAFENIB CHEMBL1336	2005
	IMATINIB CHEMBL941	2001
	IMATINIB MESYLATE CHEMBL1642	2001

← Target Page

Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T09:38:23Z

Source · ChEMBL 36 via Core Engine Freshness · Sep 13, 2026, 6:38 PM KST As of · Sep 13, 2026

ChEMBL ChEMBL 36 CHEMBL2007